Clinical Trials & Academic Partnerships

Alzheimer's Study

Renew ECP Therapy
Renew® NCP-5 for theTreatment of Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type is a randomized, pivotal, single blind, parallel design, multi-site study intended to examine the efficacy and safety of Renew® NCP-5 therapy in the treatment of Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type. The lead clinical site is at Kansas University Alzheimer’s Disease Center and the lead imaging site is at Mass General Brigham’s/Harvard Medical School.

View details at ClinicalTrials.gov 

Learn more about the Renew® NCP-5 

Academic Partnerships

College Lab Student with Instructor

Renew Research works with top academic research institutions including Harvard Medical School/MGH-Martinos Center for Biomedical Imaging, Kansas University Medical Center, and University of California San Diego along with other institutions across the globe to conduct cutting-edge clinical research using the most advanced technologies and smart study design principles in the following areas:

  • Neurology
  • Concussion
  • Sports and Wellness
  • Cardiovascular Research
  • Surgical
  • Supplements
  • Diagnostics
  • Software as a Medical Device